--- title: "Achieve Life Sciences (ACHV) news: going concern and offering" url: "https://aibio.space/companies/achieve-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ACHV going concern and offering news: Achieve Life Sciences prices $45,000,000 offering of stock and warrants at $3.00. Achieve Life Sciences, Inc." --- ACHV Achieve Life Sciences, Inc. NASDAQ · United States # Achieve Life Sciences (ACHV) news ACHV going concern and offering news Financings · 2026-04-16 ## [Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down](https://aibio.space/news/achieve-life-sciences-agrees-180-million-private-placement-ceo-richard/) Achieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026. ## Latest Achieve Life Sciences news 1. 2025-06-26 Financings [Achieve Life Sciences prices $45,000,000 offering of stock and warrants at $3.00](https://aibio.space/news/achieve-life-sciences-prices-45-000-000-offering-stock-warrants-3-00/) Achieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning. ## Achieve Life Sciences at a glance - **Ticker**: ACHV - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $187.3 million ### Related companies - [EAGLE PHARMACEUTICALS INC](https://aibio.space/companies/eagle-pharmaceuticals/) OTC: EGRX - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) NASDAQ: SGMT - [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO - [Quoin Pharmaceuticals](https://aibio.space/companies/quoin-pharmaceuticals/) NASDAQ: QNRX - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NASDAQ: NBP - [ProtoKinetix](https://aibio.space/companies/protokinetix/) OTC: PKTX - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) NASDAQ: SRPT ### Also on NASDAQ - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [ICU MEDICAL INC/DE](https://aibio.space/companies/icu-medical-de/) ICUI - [Glucotrack](https://aibio.space/companies/glucotrack/) GCTK - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) CNSP - [10x Genomics](https://aibio.space/companies/10x-genomics/) TXG ## Achieve Life Sciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | | [$22.8 million](https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/) | | Net income (loss) | [-$54.6 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | [-$39.8 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | | Cash from operations | [-$49.5 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | [-$29.8 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | | Cash and equivalents | [$20.9 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526344624/) | [$12.8 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | | Short-term investments | [$15.5 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526344624/) | [$21.6 million](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $48.0 million, plus short-term investments of $139.3 million, $187.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Achieve Life Sciences Has Achieve Life Sciences issued a going-concern warning? Our latest story on this, dated Jun 26, 2025: "Achieve Life Sciences prices $45,000,000 offering of stock and warrants at $3.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/achieve-life-sciences-prices-45-000-000-offering-stock-warrants-3-00/). Has Achieve Life Sciences raised money recently? Our latest story on this, dated Apr 16, 2026: "Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/achieve-life-sciences-agrees-180-million-private-placement-ceo-richard/). What is the ticker symbol of Achieve Life Sciences? Achieve Life Sciences, Inc. trades under the ticker ACHV on NASDAQ. Where is Achieve Life Sciences listed? Achieve Life Sciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:SP4P. What is the SEC CIK of Achieve Life Sciences? The SEC Central Index Key (CIK) for Achieve Life Sciences, Inc. is 949858. Its filings are on SEC EDGAR. How many shares does Achieve Life Sciences have outstanding? 102,902,490 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Achieve Life Sciences listed under? Our directory records Achieve Life Sciences, Inc. under United States. What does Achieve Life Sciences do? Our directory classifies Achieve Life Sciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Achieve Life Sciences? The ISIN recorded for Achieve Life Sciences, Inc. is US0044685008. Does aibio.space cover Achieve Life Sciences? aibio.space lists Achieve Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Achieve Life Sciences incorporated? SEC records list its state or country of incorporation as DE. Is Achieve Life Sciences profitable? Achieve Life Sciences, Inc. reported a net loss of $54.6 million for the fiscal year ended Dec 31, 2025, and used $49.5 million of cash in operations, per its annual report to the SEC. How much cash does Achieve Life Sciences have? $187.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Achieve Life Sciences (ACHV) stock news? Our latest story on Achieve Life Sciences, dated Apr 16, 2026: "Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down". Achieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026. [Source](https://aibio.space/news/achieve-life-sciences-agrees-180-million-private-placement-ceo-richard/). How long will Achieve Life Sciences's cash last? From our story of Jun 26, 2025: The company's 2024 annual report carried a going-concern warning. [Source](https://aibio.space/news/achieve-life-sciences-prices-45-000-000-offering-stock-warrants-3-00/). ## Investor discussion: Achieve Life Sciences Members talk about Achieve Life Sciences (ACHV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Achieve Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-08-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/949858/000119312526352154/prospectussupplementaug2.htm) 2. 2026-05-12 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/949858/000119312526219441/achv-20260512.htm) 3. 2026-04-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/949858/000119312526159189/achv-ex99_1.htm) 4. 2026-03-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm) 5. 2026-01-23 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/949858/000119312526021032/achv-20260123.htm) 6. 2025-06-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/949858/000095017025090401/prelimprosuppjune2025-pr.htm) 7. 2025-03-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/achv-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ACHV on TradingView](https://www.tradingview.com/symbols/NASDAQ-ACHV/). ## SEC filings and registration - **SEC name**: Achieve Life Sciences, Inc. - **CIK**: 949858 - **Industry (SIC)**: In Vitro & In Vivo Diagnostic Substances (2835) - **US tickers**: ACHV (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 22722 29TH DR. SE, SEATTLE, WA, 98021 - **Phone**: 425-686-1500 - **Shares outstanding**: 102,902,490 as of 2026-08-11 (10-Q filed 2026-08-11) - **Former names**: ONCOGENEX PHARMACEUTICALS, INC.; SONUS PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/949858/000119312526410781/achv-20261001.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/achv-20260814.htm) filed 2026-08-14 - [424B5](https://www.sec.gov/Archives/edgar/data/949858/000119312526352154/prospectussupplementaug2.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/949858/000119312526344624/achv-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/949858/000119312526344571/achv-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/949858/000119312526296174/achv-20260702.htm) filed 2026-07-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/949858/000094985826000006/achv-20260604.htm) filed 2026-06-08 - [8-K](https://www.sec.gov/Archives/edgar/data/949858/000119312526252624/achv-20260529.htm) filed 2026-06-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000949858), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Achieve Life Sciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACHV, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Achieve Life Sciences, Inc. - **Ticker**: ACHV - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0044685008 - **Other listed symbols**: GETTEX:SP4P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ACHV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/achieve-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Achieve Life Sciences (ACHV) news: going concern and offering", 2026-10-31, https://aibio.space/companies/achieve-life-sciences/